Immix Biopharma (IMMX) Competitors $2.17 -0.05 (-2.25%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMMX vs. SOPH, BMEA, XBIT, INBX, CRDF, LFVN, SLN, CMPX, MGNX, and CADLShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include SOPHiA GENETICS (SOPH), Biomea Fusion (BMEA), XBiotech (XBIT), Inhibrx (INBX), Cardiff Oncology (CRDF), LifeVantage (LFVN), Silence Therapeutics (SLN), Compass Therapeutics (CMPX), MacroGenics (MGNX), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. SOPHiA GENETICS Biomea Fusion XBiotech Inhibrx Cardiff Oncology LifeVantage Silence Therapeutics Compass Therapeutics MacroGenics Candel Therapeutics SOPHiA GENETICS (NASDAQ:SOPH) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Which has more risk and volatility, SOPH or IMMX? SOPHiA GENETICS has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Which has higher valuation and earnings, SOPH or IMMX? Immix Biopharma has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$64.49M3.30-$78.98M-$1.09-2.99Immix BiopharmaN/AN/A-$15.43M-$0.85-2.55 Do institutionals & insiders believe in SOPH or IMMX? 31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 48.9% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor SOPH or IMMX? In the previous week, Immix Biopharma had 1 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for Immix Biopharma and 5 mentions for SOPHiA GENETICS. Immix Biopharma's average media sentiment score of 0.83 beat SOPHiA GENETICS's score of 0.32 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immix Biopharma 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in SOPH or IMMX? SOPHiA GENETICS received 10 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 73.08% of users gave SOPHiA GENETICS an outperform vote. CompanyUnderperformOutperformSOPHiA GENETICSOutperform Votes1973.08% Underperform Votes726.92% Immix BiopharmaOutperform Votes9100.00% Underperform VotesNo Votes Is SOPH or IMMX more profitable? Immix Biopharma has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -110.71%. SOPHiA GENETICS's return on equity of -55.06% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-110.71% -55.06% -38.33% Immix Biopharma N/A -102.68%-80.89% Do analysts recommend SOPH or IMMX? SOPHiA GENETICS presently has a consensus price target of $7.40, suggesting a potential upside of 126.99%. Immix Biopharma has a consensus price target of $7.00, suggesting a potential upside of 222.58%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Immix Biopharma is more favorable than SOPHiA GENETICS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Immix Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryImmix Biopharma beats SOPHiA GENETICS on 10 of the 17 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.69M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-2.5510.5990.0517.18Price / SalesN/A195.801,117.00116.99Price / CashN/A57.1642.9637.86Price / Book2.685.094.784.78Net Income-$15.43M$151.83M$120.31M$225.60M7 Day Performance6.37%-2.13%-1.92%-1.23%1 Month Performance29.17%-3.10%11.50%3.36%1 Year Performance-69.61%11.54%30.59%16.60% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma2.8749 of 5 stars$2.17-2.3%$7.00+222.6%-67.7%$59.69MN/A-2.559News CoverageSOPHSOPHiA GENETICS2.445 of 5 stars$3.28flat$6.50+98.2%-25.9%$214.45M$62.37M-3.01520Analyst ForecastNews CoveragePositive NewsBMEABiomea Fusion3.899 of 5 stars$5.88+4.3%$39.36+569.4%-69.2%$213.09MN/A-1.4150Analyst ForecastXBITXBiotechN/A$6.98+0.4%N/A+61.9%$212.77M$4.01M-6.41100INBXInhibrx1.4866 of 5 stars$14.58-0.3%N/A-49.7%$211.06M$1.57M0.00166CRDFCardiff Oncology2.0224 of 5 stars$4.07+3.8%$10.33+153.9%+195.8%$208.10M$490,000.00-4.1720LFVNLifeVantage4.5505 of 5 stars$16.30+1.6%N/A+178.9%$204.16M$196.01M50.13260Analyst ForecastNews CoveragePositive NewsSLNSilence Therapeutics3.4422 of 5 stars$6.77+5.0%$57.20+744.9%-59.0%$202.63M$31.55M-4.11100CMPXCompass Therapeutics2.6583 of 5 stars$1.47+0.3%$6.75+360.8%-13.2%$201.57M$850,000.00-4.0720MGNXMacroGenics3.5336 of 5 stars$3.20flat$7.63+138.3%-67.7%$200.84M$139.77M-2.03430Positive NewsCADLCandel Therapeutics2.9082 of 5 stars$6.13-9.2%$11.00+79.4%+681.3%$199.08M$120,000.00-3.6060Analyst ForecastInsider TradeAnalyst RevisionGap DownHigh Trading Volume Related Companies and Tools Related Companies SOPHiA GENETICS Competitors Biomea Fusion Competitors XBiotech Competitors Inhibrx Competitors Cardiff Oncology Competitors LifeVantage Competitors Silence Therapeutics Competitors Compass Therapeutics Competitors MacroGenics Competitors Candel Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMMX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMMX Stock Alerts